Preparation and application of a class of sulfonic acid-phosphonic acid ligands

Abstract

The present invention relates to the preparation and application of a class of sulfonic acid-phosphonic acid ligands. The sulfonic acid-phosphonic acid ligand structure includes sulfonic acid, quaternary ammonium and phosphonic acid groups, and specifically includes sulfobetaine-phosphonic acid ligands, sulfonic acid-zoledronic acid ligands and sulfonic acid-phosphonic acid ligands Sedronic acid ligand; sulfobetaine-phosphonic acid ligand molecular formula is: C 8 H 21 NO 10 P 2 S, the molecular weight is 384.2; the molecular formula of the sulfonic acid-zoledronic acid ligand is: C 8 H 16 O 10 N 2 P 2 S, the molecular weight is 394.23; the molecular formula of the sulfonic acid-risedronic acid ligand is: C 10 H 17 O 10 NP 2 S, the molecular weight is 405.25. The sulfonic acid-phosphonic acid ligand of the invention has excellent hydrophilicity and can coordinate with various metal elements. Such molecules have important applications in the following two aspects: first, to modify hydrophobic nanomaterials, thereby significantly improving the hydrophilicity of the materials and making them dispersible in the aqueous phase; second, to have a certain inhibitory effect on tumors.

Description

technical field [0001] The invention belongs to the technical field of biological materials, and in particular relates to the preparation and application of a class of sulfonic acid-phosphonic acid ligands. Background technique [0002] Inorganic nanomaterials have attracted extensive attention in the field of biomedicine because of their unique physical and chemical properties. For example, materials such as magnetic iron oxide particles, semiconductor quantum dots, and up-conversion luminescent nanoparticles have outstanding performance in the application research of analytical sensing, biomarkers, imaging, and disease treatment. However, the clinical transformation of these materials, especially when applied to the human body, is very limited. At present, very few inorganic nanomaterials have been clinically approved for use in the human body. The main reason is that inorganic nanomaterials are easily detected by the immune system after entering the body Capture, in the ...

AI Technical Summary

Problems solved by technology

Although the polymer-based phase inversion method can prepare inorganic nanoparticles with good hydrophilicity, there are two problems in this method: (1) the preparation process of amphiphilic polymers and end-group modified polymers is relatively complicated and requires a lot of High chemical synthesis skills, high synthesis cost

(2) The molecular weight of the polymer is often very large, and the modification on the surface of the nanoparticle inevitably increases its overall particle size (hydration particle size). Even if the inner particle size of the nanoparticle is extremely small, it is often impossible to Metabolized by glomerular filtration

However, ZDS is easily oxidized and has limited interactions with inorganic nanoparticles other than iron oxide, so its application range as a phase transition ligand is limited.

[0005] From the above background, it can be seen that the currently reported phase transition schemes have their own defects, and it is still necessary to develop efficient and adaptable new ligands for the phase transition of inorganic nanoparticles.

Images